在过去四十年中，尽管死亡率有所下降，但乳腺癌的发病率一直在增加。内分泌治疗和化疗是最常用的癌症治疗选择，但这些疗法仍然存在一些障碍。智能材料，例如用于靶向、递送和释放活性成分的纳米载体，对内在刺激（pH响应、氧化还原响应、酶响应和热响应）和外在刺激（超声波响应、磁响应）敏感响应性、光响应性）已被作为乳腺癌治疗的新策略进行研究。环糊精 (CD) 用于设计这些刺激响应药物载体和递送系统，通过与疏水分子的包合物或与大型结构的共价键来生成新材料。目前的工作旨在收集和整合基于 CD 的刺激响应系统的体外和体内临床前研究的最新数据，以促进乳腺癌治疗的研究。所有药物载体在刺激下均表现出较高的体外释放率。刺激响应纳米平台表现出生物相容性和令人满意的IC50结果、对细胞活力的抑制以及对多种乳腺癌细胞系的抗肿瘤活性。此外，这些系统导致药物剂量显着减少，这鼓励了可能的临床研究，以寻找传统抗肿瘤疗法的更好替代方案。版权所有© Bentham Science Publishers；如有任何疑问，请发送电子邮件至 epub@benthamscience.net。

The incidence of breast cancer has been increasing over the last four decades, although the mortality rate has decreased. Endocrine therapy and chemotherapy are the most used options for cancer treatment but several obstacles are still attributed to these therapies. Smart materials, such as nanocarriers for targeting, delivery and release of active ingredients, sensitive to intrinsic-stimuli (pH-responsive, redox-responsive, enzyme- responsive, and thermo-responsive) and extrinsic-stimuli (ultrasound-responsive, magnetic-responsive, light-responsive) have been studied as a novel strategy in breast cancer therapy. Cyclodextrins (CDs) are used in the design of these stimuli-responsive drug carrier and delivery systems, either through inclusion complexes with hydrophobic molecules or covalent bonds with large structures to generate new materials. The present work aims to gather and integrate recent data from in vitro and in vivo preclinical studies of CD-based stimuli- responsive systems to contribute to the research in treating breast cancer. All drug carriers showed high in vitro release rates in the presence of a stimulus. The stimuli-responsive nanoplatforms presented biocompatibility and satisfactory results of IC50, inhibition of cell viability and antitumor activity against several breast cancer cell lines. Additionally, these systems led to a significant reduction in drug dosages, which encouraged possible clinical studies for better alternatives to traditional antitumor therapies.Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.